A hospital based comparative study to assess the safety and efficacy of various adjuvant therapies in androgenetic alopecia among adult male

INTRODUCTION: Androgenetic Alopecia (AGA) is the most common form of hair loss in men.Platelet-rich plasma (PRP) is a source of growth factors derived from a platelet concentrate and is being used in hair regrowth in patients of AGA. Injectable-platelet-rich fibrin (iPRF) is advancedversion of platelet-rich fibrin in liquid form which can be injected and contains stem cells with high regenerative potential. OBJECTIVES:This study aims to compare the efficacy and safety of platelet rich plasma(PRP) and injectable platelet rich fibrin(i-PRF) as therapeutic options for AGA over conventional therapy assessing improvement in hair density, alopecia grade, and patient satisfaction. METHODS: A randomized controlled trial was conducted with 90 male patients diagnosed with AGA, divided equally into three treatment groups: conventional therapy, PRP and i-PRF. Participants received 4 treatment sessions at monthly intervals. Efficacy was evaluated through  photographic assessments, hair density and alopecia grade and patient satisfaction score. RESULTS: Preliminary findings indicate both PRP and i-PRF significantly improve hair count and alopecia grade compared to baseline measurements (p<0.05). However there is also a significant difference observed in hair density between three groups with i-PRF patients showed maximum 22.39% of increase in hair density while patient with PRP showed 13.09 % improvement and patient with conventional therapy showed 8.5% improvement. Conclusion: Both PRP and iPRF are effective and safe treatments for AGA, enhancing hair regrowth and achieving high patient satisfaction i-PRF ease of preparation and potential for sustained release of growth factors could make it a preferable choice over conventional treatment.